FAQ on Tonix Pharmaceuticals' TNX-801 Vaccine for Mpox and Smallpox
Summary
Tonix Pharmaceuticals has published promising data on TNX-801, a vaccine showing reduced virulence and protection against mpox and smallpox, positioning it as a potential solution for current public health emergencies.
What is TNX-801?
TNX-801 is a recombinant chimeric horsepox virus vaccine developed by Tonix Pharmaceuticals, showing significantly reduced virulence compared to traditional vaccinia vaccines and providing protection against Clade Ia monkeypox in preclinical studies.
Why is TNX-801 important?
With the World Health Organization declaring new public health emergencies for Clade Ib and IIb mpox, TNX-801 is positioned as a single-dose vaccine candidate aimed at durable protection against these outbreaks, offering broad, long-lasting immunity against both mpox and smallpox.
How does TNX-801 compare to traditional vaccines?
TNX-801 shows significantly reduced virulence compared to traditional vaccinia vaccines and is designed to provide durable protection with a single dose, potentially offering a safer and more effective alternative.
Who is developing TNX-801?
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated biopharmaceutical company, is developing TNX-801, along with other therapies for pain management and public health challenges.
When will TNX-801 be available?
Tonix is advancing TNX-801’s development with FDA feedback, collaborations for large-scale manufacturing, and planned clinical trials in Kenya, but the exact availability date is not specified in the content.
Where is TNX-801 being developed?
Tonix owns and operates a state-of-the-art infectious disease research facility in Frederick, Maryland, and a GMP-capable advanced manufacturing facility in Dartmouth, Maryland, for TNX-801 production.
What are the implications of TNX-801 for public health?
TNX-801 could offer a significant advancement in the fight against mpox and smallpox, providing a single-dose vaccine with durable protection, which is crucial for managing current and future outbreaks.
How can I learn more about Tonix Pharmaceuticals and TNX-801?
For more information, visit Tonix Pharmaceuticals’ website at www.TonixPharma.com or the company’s newsroom at https://ibn.fm/TNXP.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 125295